Effectiveness and safety of Levosimendan treatment in patients with acute heart failure
Objective This study aimed to evaluate the clinical application effect of Levosimendan in patients with acute heart failure(AHF).Methods A total of 98 patients with AHF admitted to Tongchuan People's Hospital from January 2021 to October 2023 were included in this study and were randomly divided into two groups,with 49 patients in each group.There were 27 males and 22 females in the control group,the age was(67.14±6.65)years old,and the New York Heart Association(NYHA)grading was grade Ⅱ in 20 cases,grade Ⅲ in 15 cases,and grade Ⅳ in 14 cases.There were 28 males and 21 females in the observation group,the age was(66.57±6.64)years old,and the NYHA grading was grade Ⅱ in 19 cases,grade Ⅲ in 16 cases,and grade Ⅳ in 14 cases.The control group received standard treatment,and the observation group received standard treatment plus Levosimendan(intravenous injection),with a treatment period of 4 weeks.The duration of clinical symptoms(chest tightness and shortness of breath),myocardial enzyme levels[myeloperoxidase(MPO),N-terminal pro B-type natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI),and matrix metalloproteinase 9(MMP-9)],and cardiac function indicators[left ventricular diameter(LVD),left atrial diameter(LAD),Left ventricular short axis shortening fraction(LVFS),tricuspid annular plane systolic excursion(TAPSE),and heart rate(HR)]before and after treatment,as well as the occurrence of adverse reactions during treatment were compared between the two groups.Independent sample t test and x2 test were used.Results After treatment,the duration of chest tightness[(1.82±0.37)min/time]and dyspnea[(1.68±0.39)min/time]in the observation group were shorter than those in the control group[(2.49±0.42)min/time and(2.59±0.41)min/time],with statistically significant differences(both P＜0.05).The levels of MPO[(2.89±0.61)pg/L],NT-proBNP[(2.05±0.67)g/L],cTnI[(2.58±0.56)μg/L],and MMP-9[(58.58±7.41)μg/L]in the observation group were lower than those in the control group[(4.36±0.83)pg/L,(4.69±1.54)g/L,(2.97±0.63)μg/L,and(90.64±8.84)μg/L],with statistically significant differences(all P＜0.05).The levels of LVD[(40.44±4.84)mm]and LVFS[(31.41±2.54)％]in the observation group were higher than those in the control group[(32.65±4.64)mm and(22.63±3.68)％],while the levels of LAD[(29.89±3.38)mm],TAPSE[(15.85±3.03)mm],and HR[(69.85±8.23)beats/min]were lower than those in the control group[(37.65±4.65)mm,(17.59±3.13)mm,and(86.52±8.51)beats/min],with statistically significant differences(all P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Levosimendan shows good efficacy and safety in patients with AHF and can be considered an effective treatment option for this condition.
万方数据
维普
